234 related articles for article (PubMed ID: 11110504)
1. Glucagon-like peptide (GLP)-1 and leptin concentrations in obese patients with Type 2 diabetes mellitus.
Mannucci E; Ognibene A; Cremasco F; Bardini G; Mencucci A; Pierazzuoli E; Ciani S; Fanelli A; Messeri G; Rotella CM
Diabet Med; 2000 Oct; 17(10):713-9. PubMed ID: 11110504
[TBL] [Abstract][Full Text] [Related]
2. Effects of metformin on glucagon-like peptide-1 levels in obese patients with and without Type 2 diabetes.
Mannucci E; Tesi F; Bardini G; Ognibene A; Petracca MG; Ciani S; Pezzatini A; Brogi M; Dicembrini I; Cremasco F; Messeri G; Rotella CM
Diabetes Nutr Metab; 2004 Dec; 17(6):336-42. PubMed ID: 15887627
[TBL] [Abstract][Full Text] [Related]
3. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.
Nauck MA; Heimesaat MM; Orskov C; Holst JJ; Ebert R; Creutzfeldt W
J Clin Invest; 1993 Jan; 91(1):301-7. PubMed ID: 8423228
[TBL] [Abstract][Full Text] [Related]
4. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus.
Vilsbøll T; Krarup T; Sonne J; Madsbad S; Vølund A; Juul AG; Holst JJ
J Clin Endocrinol Metab; 2003 Jun; 88(6):2706-13. PubMed ID: 12788877
[TBL] [Abstract][Full Text] [Related]
5. Evidence for early impairment of glucagon-like peptide 1-induced insulin secretion in human type 2 (non insulin-dependent) diabetes.
Lugari R; Dei Cas A; Ugolotti D; Finardi L; Barilli AL; Ognibene C; Luciani A; Zandomeneghi R; Gnudi A
Horm Metab Res; 2002 Mar; 34(3):150-4. PubMed ID: 11972305
[TBL] [Abstract][Full Text] [Related]
6. Normalization of fasting glycaemia by intravenous GLP-1 ([7-36 amide] or [7-37]) in type 2 diabetic patients.
Nauck MA; Weber I; Bach I; Richter S; Orskov C; Holst JJ; Schmiegel W
Diabet Med; 1998 Nov; 15(11):937-45. PubMed ID: 9827848
[TBL] [Abstract][Full Text] [Related]
7. Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects.
Mannucci E; Ognibene A; Cremasco F; Bardini G; Mencucci A; Pierazzuoli E; Ciani S; Messeri G; Rotella CM
Diabetes Care; 2001 Mar; 24(3):489-94. PubMed ID: 11289473
[TBL] [Abstract][Full Text] [Related]
8. Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects.
Vilsbøll T; Agersø H; Krarup T; Holst JJ
J Clin Endocrinol Metab; 2003 Jan; 88(1):220-4. PubMed ID: 12519856
[TBL] [Abstract][Full Text] [Related]
9. No hypoglycemia after subcutaneous administration of glucagon-like peptide-1 in lean type 2 diabetic patients and in patients with diabetes secondary to chronic pancreatitis.
Knop FK; Vilsbøll T; Larsen S; Madsbad S; Holst JJ; Krarup T
Diabetes Care; 2003 Sep; 26(9):2581-7. PubMed ID: 12941722
[TBL] [Abstract][Full Text] [Related]
10. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients.
Willms B; Werner J; Holst JJ; Orskov C; Creutzfeldt W; Nauck MA
J Clin Endocrinol Metab; 1996 Jan; 81(1):327-32. PubMed ID: 8550773
[TBL] [Abstract][Full Text] [Related]
11. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients.
Vilsbøll T; Krarup T; Madsbad S; Holst JJ
Diabetologia; 2002 Aug; 45(8):1111-9. PubMed ID: 12189441
[TBL] [Abstract][Full Text] [Related]
12. The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype.
Vilsbøll T; Knop FK; Krarup T; Johansen A; Madsbad S; Larsen S; Hansen T; Pedersen O; Holst JJ
J Clin Endocrinol Metab; 2003 Oct; 88(10):4897-903. PubMed ID: 14557471
[TBL] [Abstract][Full Text] [Related]
13. Racial differences in glucagon-like peptide-1 (GLP-1) concentrations and insulin dynamics during oral glucose tolerance test in obese subjects.
Velasquez-Mieyer PA; Cowan PA; Umpierrez GE; Lustig RH; Cashion AK; Burghen GA
Int J Obes Relat Metab Disord; 2003 Nov; 27(11):1359-64. PubMed ID: 14574347
[TBL] [Abstract][Full Text] [Related]
14. Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients.
Creutzfeldt WO; Kleine N; Willms B; Orskov C; Holst JJ; Nauck MA
Diabetes Care; 1996 Jun; 19(6):580-6. PubMed ID: 8725855
[TBL] [Abstract][Full Text] [Related]
15. No reactive hypoglycaemia in Type 2 diabetic patients after subcutaneous administration of GLP-1 and intravenous glucose.
Vilsbøll T; Krarup T; Madsbad S; Holst JJ
Diabet Med; 2001 Feb; 18(2):144-9. PubMed ID: 11251679
[TBL] [Abstract][Full Text] [Related]
16. Overnight GLP-1 normalizes fasting but not daytime plasma glucose levels in NIDDM patients.
Willms B; Idowu K; Holst JJ; Creutzfeldt W; Nauck MA
Exp Clin Endocrinol Diabetes; 1998; 106(2):103-7. PubMed ID: 9628239
[TBL] [Abstract][Full Text] [Related]
17. Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM.
Nauck MA; Wollschläger D; Werner J; Holst JJ; Orskov C; Creutzfeldt W; Willms B
Diabetologia; 1996 Dec; 39(12):1546-53. PubMed ID: 8960841
[TBL] [Abstract][Full Text] [Related]
18. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.
Nauck MA; Kleine N; Orskov C; Holst JJ; Willms B; Creutzfeldt W
Diabetologia; 1993 Aug; 36(8):741-4. PubMed ID: 8405741
[TBL] [Abstract][Full Text] [Related]
19. Impact of Sleeve Gastrectomy on Type 2 Diabetes Mellitus, Gastric Emptying Time, Glucagon-Like Peptide 1 (GLP-1), Ghrelin and Leptin in Non-morbidly Obese Subjects with BMI 30-35.0 kg/m
Vigneshwaran B; Wahal A; Aggarwal S; Priyadarshini P; Bhattacharjee H; Khadgawat R; Yadav R
Obes Surg; 2016 Dec; 26(12):2817-2823. PubMed ID: 27185177
[TBL] [Abstract][Full Text] [Related]
20. Orlistat augments postprandial increases in glucagon-like peptide 1 in obese type 2 diabetic patients.
Damci T; Yalin S; Balci H; Osar Z; Korugan U; Ozyazar M; Ilkova H
Diabetes Care; 2004 May; 27(5):1077-80. PubMed ID: 15111524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]